Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells

NCT00458679 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia (CLL)

Interventions

BIOLOGICAL: CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS VACCINE

Sponsor

Baylor College of Medicine

Collaborators

[object Object]
[object Object]